Paul Hauptman, M.D., of the Department of Internal Medicine-Cardiology, published an editorial in the New England Journal of Medicine reviewing the results of the Trail of Ularitide Efficacy and Safety in Acute Heart Failure (TRUE-AHF) study. The purpose of the study was to determine the safety and effectiveness of a new synthetic drug, “ularitide”, in treating patients with acute decompensated heart failure (ADHF).

ADHF is a worsening of heart failure symptoms such as difficulty breathing, fatigue, and swelling of legs or feet. The trial sought to determine if a single treatment with ularitide would improve symptoms and if rapid treatment would improve long-term survival. However, it was found that the effects of treatment were limited and short-lived.

For more information, read the full article in Newslink.